Proprotein convertases (PCs) are serine proteases with an active role in the post-translational processing of numerous inactive proteins to active proteins including many substrates of paramount importance in cancer development and progression. Furin (PCSKC3), a well-studied member of this family, is overexpressed in numerous human and experimental malignancies. In the present communication, we treated two furin-overexpressing non-small cell carcinoma (NSCLC) cell lines (Calu-6 and HOP-62) with the PC inhibitor CMK (Decanoyl-Arg-Val-Lys-Arg-chloromethylketone). This resulted in a diminished IGF-1R processing and a simultaneous decrease in cell proliferation of two NSCLC lines. Similarly, growth of subcutaneous xenografts of both cell lines, were partially inhibited by an in vivo treatment with the same drug. These observations point to a potential role of PC inhibitors in cancer therapy.
INTRODUCTION
Proprotein convertases (PCs) are serine proteases with an active role in the post-translational activation of numerous inactive proteins to active proteins of great biological relevance [1, 2] . The PC family comprises several members, PC1/3 (PSCK1), PC2 (PCSK2), Furin (PCSK3), PC4 (PCSK4), PC5/6 (PCSK5), PACE4 (PCSK6), PC7/8 (PCSK7) SKI-1 (PCSK8), and NARC-1 (PCSK9). PCs recognize and cleave substrates mostly within the general motif (K/R)-(X) n -(K/R)#, where n ¼ 0, 2, 4, or 6 and X any amino acid, yet they are not completely redundant, as shown by their different substrates preferences, pattern of inhibition, and phenotypes of the different PC's knockout animals [2, 3] . Many of the PCs protein substrates have a direct role in tumor progression, as matrix-degrading enzymes [4] , growth factors and their receptors, adhesion proteins, and others [5, 6] . Furthermore, PCs are overexpressed in numerous malignancies from different sites such as skin, head, and neck, ovary, prostate, colon, and others [7] [8] [9] [10] [11] [12] . Among all PCs, furin has been the most studied in the context of tumor growth and progression. Furin processes into its mature form and activates stromelysin 3, a MMP involved in tumor invasion, [13] . Similarly, furin activates a family of MMPs, known as membrane type metalloproteinases (MT-MMPs) also involved in tumor invasion and degradation of the extracellular matrix, and several other biomolecules involved in tumor development and progression such as TGF beta, IGF-1R, VEGF-C [1, [14] [15] [16] [17] [18] . Thus, furin is an attractive candidate as a therapeutic target in human cancer because it is overexpressed in human cancer cell lines and primary squamous cell carcinomas from lung, head, and neck among many others [8] . In addition, previous reports on PCs and cancer describe the increase expression of PCs in primary lung cancers and the possible use of furin as a tumor marker, that is, furin is overexpressed in non-small cell lung carcinoma and not in small cell carcinomas and has been proposed as a marker to differentiate between these two tumor types [19] [20] [21] . Given furin's role in processing cancer relevant substrates, its inhibition could open a new therapeutic alternative, either used alone or in combination with other drugs in the treatment of lung cancer.
The use of PC inhibitors, alpha 1-PDX (PDX) and CMK (decanoyl-Arg-Val-Lys-Arg-chloromethylketone), have been successfully used in pilot studies (reviewed in 22) . Herein, we propose to evaluate a panel of lung cancer cell lines for furin levels and treat a selected group of cancer cell lines endogenously producing high levels of furin with CMK. The hypothesis behind this approach is that inhibition of PCs will abolish or significantly reduce the growth and proliferation of lung cancer cells.
MATERIALS AND METHODS

Cell Lines
A series of human non-small cell lung cancer cell lines were used for this study. The cell lines were obtained from ATCC: Calu-1, Calu-6, A 549, NCI-H226, NCI-H460, NCI-H520, NCI-H522, HOP-92, and HOP-62.
Western Blot Analyses and Immunohistochemistry
Proteins (50 mg cell lysates per experimental condition as described previously [7] were separated using an 8% SDS-PAGE. Antibodies used for immunoblot analysis included anti-IGF-1R b-subunit [C-20, sc-713, Santa Cruz, CA]) and furin monoclonal antibody MON-152 (ALX-803-017; ALEXIS). The quantification of Western blot results was performed by using ImageJ developed by the National Institutes of Health. Furin IHC was performed with the same antibody using paraffin-embedded normal lung and tumors. P-Histone 3 immunohistochemistry was used to detect cells in the G2-M phases of mitosis. The primary anti phospho-Histo 3 (ser10) rabbit antibody, catalog number 9701, from Cell Signaling (Danvers, MA) was applied to paraffin sections as recommended by the supplier. Once stained, the mitotic index was calculated by counting labeled p-Histone 3 cells per 200Â field (each field equivalent to 0.32 mm 2 ) in ten to fifteen fields per tumor. A total of five control and five CMK treated xenotransplants were used per cell line xenografts. All paraffin sections were subjected to a previously published immunostaining protocol using positive and negative controls [8, 9] . All specimens were analyzed and counted using a Nikon Optiphot with a Plan/Apo objective 20Â, NA, 0.75, Nikon eyepiece Â10, final magnification Â200.
CMK Treatments
Cells were treated with a general convertase inhibitor, CMK (decanoyl-Arg-Val-Lys-Arg-chloromethylketone), ALX-260-022, Enzo Life Sciences, Plymouth Meeting, PA) at different concentrations (50 and 100 mM). Twenty-four hours after CMK treatment, cells were lysed and subjected to Western blot analysis for IGF-1Rb. 
Cell Growth Assay
In Vivo Tumorigenicity
A total of 2.5 million Calu-6 or HOP-62 cells per mouse were inoculated sc into 10 nude mice per cell line. Tumors were detected 7 days after cell inoculation, and the initial volume was measured (50-100 mm 3 ). At this stage, CMK, dissolved in DMSO:PBS (1:10) to a final concentration of 200 mM, was injected intratumorally. Control animals (n ¼ 5) were injected with the vehicle only. Tumors were measured every other day using a Vernier caliper. Volumes (V) of the tumors were obtained by using the following equation:
526, where L1 and L2 are the length and width of the s.c. tumor. The statistical significance of the differences of tumor development and mitotic indices were calculated using a Wilcoxon two sample tests and/or two tailed t-test.
RESULTS
Expression Levels of Furin in Tumor Cell Lines and Primary Tumors
After the detection of proprotein convertase (PC) expression in human cell lines was completed using RT-PCR we confirmed by Western analysis that most human non-small cell lung cancer (NSCLC) cell lines (5/9) expressed furin protein ( Figure 1A ). Two cell lines expressed higher levels of furin expression (Calu-6 and HOP-62) than any of the other cell lines, whereas high to moderate expression was seen in A549, NCI-H460, and H522 cell lines and was minimal to absent in Calu-1, HOP-92, NCI H-520, and NCI H-526 cells. Immunohistochemical analysis showed that normal bronchial epithelium was negative for furin ( Figure 1B ) and 17 intraepithelial neoplastic lesions of the bronchi (dysplastic lesions and carcinoma in situ) showed moderate furin expression in approximately 50% of the lesions, especially in the basal and parabasal cells ( Figure 1C ). Human primary tumors (58 lung adenocarcinomas and 39 squamous cell carcinomas showed moderate to strong furin stain in the cytoplasm of approximately 50% and 70% of these tumors, respectively [ Figure 1D -H]). Only 16% of all tumors were negative. No significant differences were seen in tumors of different grade, stage, or survival. Thus, furin expression gradually increases during the process of tumorigenesis but reaches its peak in full-fledged invasive carcinomas.
Effects of Furin Inhibition of Lung Cancer Cells In Vitro
In order to evaluate the effects of inhibiting furin expression, Calu-6 (a high furin expressor), was transfected with furin siRNA. Knocking down furin with siRNA would thus establish a proof of principle for inhibition of this PC. As expected siRNA transfection decreased markedly the expression of furin as compared to the respective control scrambled RNAtransfected counterparts (Figure 2A) . The most effective consequence of furin inhibition was a decrease in the IGF-1R processing ( Figure 2B ) and in the proliferative ability of the knocked-down cells (reduction of up to 60% in Calu-6 cells) ( Figure 2C ). The decreased processing of the furin substrate IGF-1R (seen as an increase in the intensity of the band corresponding to the Pro IGF-1R in Figure 2B ) was detected by Western analysis. A similar result was obtained when treating the cells with the PC inhibitor CMK (Figure 3) . Treating Calu-6 ( Figure 3A and B) with 100 mM CMK reduced markedly cell proliferation (approximately 50%). This was accompanied as well by an increased accumulation of the IGF-1R pro-form, indicating a reduction in processing after CMK treatment ( Figure 3A) . The decreased activation of IGF-1R in Calu-6 cells was dose-dependent as seen in Figure 3A . This figure shows that CMK processing was inhibited using two different concentrations of CMK, with the higher dose having a marked effect on the accumulation of the pro-form. A similar gradient of inhibition of cell proliferation was seen after a short-term CMK treatment (overnight) using the same two concentrations of CMK ( Figure 3B) . A long term treatment of these cells (1 week, new dose of CMK every 2 days) showed the same effect as the short-term treatment (data not shown).
This experiment was repeated with a different NSCLC cell line, namely HOP-62, also a high furin expressor, with very similar results ( Figure 3C and D) . This cell line also showed a remarkable accumulation of the IGF-1R pro-form after exposure to different concentrations of CMK ( Figure 3C ). We also attempted to compare a single short-term exposure to CMK (24 h) versus multiple exposures (three treatments, every 2nd day the medium containing fresh CMK was replaced and proliferation was evaluated 24 h after the third treatment) (not shown). No major difference in proliferation between the two modalities was demonstrated. In both cases, the proliferation rate was reduced in approximately 33%.
Effects of Furin Inhibition on In Vivo Growth and Proliferation of Xenotransplanted Human Lung Cancer Cells
We selected the Calu-6 cell line for in vivo analysis because these cells were more sensitive to the in vitro effects of CMK than the other cell lines tested, for example, a concentration of 100 mM of CMK decreased about 50% the proliferation rate in this aggressive cell line. As can be seen in Figure 4A , CMK delayed in vivo growth, as noticed by the reduced slope in the growth rate corresponding to the treated animals. This difference in the growth rate reflected in a reduced tumor volume of approximately 45% (P ¼ 0.05-0.09 in the last four time points). A similar The proliferation changes in xenografts at the end of 3 weeks after cell inoculation was evaluated in paraffin tissue sections using immunohistochemical detection of p-histone 3, a marker of the G-M cell cycle stages, that is, a labeling index was calculated that is basically equivalent to the classical mitotic index used in pathology. This parameter showed a decrease in mitotic index after CMK treatment in both cell lines. Although the difference was more marked in CMK treated versus untreated Calu-6 cells (P ¼ 0.001) the difference was also significant when comparing treated and control HOP-62 cells (P ¼ 0.01) (Figure 4C-G) .
DISCUSSION
Furin is an ubiquitous PC that has been detected in numerous carcinomas of different types and sites. Its ability to activate a large number of cancer-associated substrates that are bonafide enhancers of the malignant phenotype and result in increased aggressiveness through tumor cell hyperproliferation and invasiveness makes this PC a promising target for cancer therapeutics. General inhibitors of PCs such as PDX and CMK have been used with success in in vitro and in vivo experimental settings [7, 16, 22, 23] . Several putative furin-specific inhibitors that have promising properties have been recently proposed [24] [25] [26] . Therapies using an autologous tumor-based product containing a plasmid encoding granulocytemacrophage colony-stimulating factor and a bifunctional short hairpin RNAi that targets furin called FANG or Vigil have been or are being evaluated in clinical trials with patients suffering from advanced cancer of the ovary, liver and sarcomas [27] [28] [29] . The mechanism of action of Vigil includes the blockage by shRNA of furin protein production. This reduction results in a decrease in conversion of transforming growth factor TGF-beta into active TGF-b 1 and -b 2 protein isoforms [15, 30] that results, among several other cancer cell changes, in inhibition of immunosuppression [31] . In our laboratory we have found that PDX inhibition decreases processing of TGF-b in head and neck squamous cell carcinoma cells and astrocytoma cell lines together with decreased growth and invasiveness of these cells [32, 33] . Other furin substrates such as MT-MMPs, stromelysin-3, and IGFR-1 were equally affected [1, 22, 32, 33] .
In the present report, we have demonstrated that PC inhibition with CMK of furin-rich lung cancer cell lines results in a diminished IGF-1R processing resulting in a decreased cell proliferation of two non-small cell lung carcinoma cell lines. In addition to IGFR-1, other PC substrates including IGF-1 itself and PDGF [34] may be involved in the PC regulation of cell proliferation. Nevertheless, IGFR-1 has been shown to be one of the most frequently involved growth factor receptors in studies investigating the role of PCs in tumor cell proliferation [1, 7, 12, 16] . Furthermore, together with decreased cell proliferation we have demonstrated that growth of subcutaneous xenografts of two NSCLC cell lines, was also partially halted by an in vivo treatment with CMK.
Taken together these results are "a proof of principle" showing that furin inhibition of NSCLC growth can be accomplished in vitro as well as in vivo. In both cases, we have found that PC inhibition was accompanied by a decrease in cell proliferation. These results open a new possibility, that is, that therapies with PC inhibitors alone or combined with traditional and novel therapeutic agents might improve the dismal prognosis of lung cancer. 
